Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.68 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | XBP1 | P17861 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | IDE | P14735 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12957482 | 0.81 | LMNA (0.57) | ERN1IGF1RLMNAPTK6MEN1 | |
| SCHEMBL1527149 | 0.81 | KDM4E (0.61) | ERN1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL27548080 | 0.81 | ERN1 (0.57) | ERN1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL38660114 | 0.81 | ALDH1A1 (0.58) | ERN1IGF1RLMNAPTK6MEN1 | |
| SCHEMBL31499448 | 0.81 | ERN1 (0.57) | ERN1LMNAKDM4EALDH1A1MAPT | |
| SCHEMBL294053 | 0.81 | ERN1 (1.00) | ERN1IGF1RLMNAMAPT | |
| SCHEMBL30159258 | 0.81 | ERN1 (1.00) | ERN1IGF1RLMNAMAPT | |
| SCHEMBL453441 | 0.80 | ERN1 (0.68) | ERN1LMNAPTK6MEN1KMT2A | |
| SCHEMBL16055174 | 0.80 | ERN1 (0.53) | ERN1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL8160732 | 0.79 | ERN1 (0.50) | ERN1IGF1RLMNAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2010-09-30 | — | — | US | claimed |
| EP-2164478-A2 | PDZ DOMAIN MODULATORS | University of Copenhagen (DK) | 2010-03-24 | — | — | EP | claimed |
| WO-2008148747-A2 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2008-12-11 | — | — | WO | claimed |
| CN-108299372-B | Medicine for preventing and treating gingivitis and preparation method thereof | 青岛新虹锐泽机械科技有限公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-2194046-B1 | Triazolone derivative | EISAI R&D MAN CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8163787-B2 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2011-05-12 | — | — | US | disclosed |
| US-7928228-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2011-04-19 | — | — | US | disclosed |
| US-7816522-B2 | Triazolone derivatives | EISAI CO., LTD. (JP) | 2010-10-19 | — | — | US | disclosed |
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | UNIVERSITY OF COPENHAGEN (DK) | 2010-09-30 | — | — | US | disclosed |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | CLARK RICHARD | 2010-07-29 | — | — | US | disclosed |
| EP-1631562-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | Pharmacia Corporation (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1615905-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | Pharmacia Corporation (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | CARTER JEFFERY (US) | 2005-07-07 | — | — | US | disclosed |
| WO-2004087687-A1 | CHROMENE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004087686-A2 | BENZOPYRAN COMPOUNDS USEFUL FOR TREATING INFLAMMATORY CONDITIONS | PHARMACIA CORPORATION (US) | 2004-10-14 | — | — | WO | disclosed |
| EP-0212095-B1 | THERMOSETTABLE COMPOUNDS PREPARED FROM MONOHYDROXY AROMATIC ALDEHYDES AND METHYLATED PYRIDINES OR PYRAZINES | THE DOW CHEMICAL COMPANY (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0212095-A1 | Thermosettable compounds prepared from monohydroxy aromatic aldehydes and methylated pyridines or pyrazines | THE DOW CHEMICAL COMPANY (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4600767-A | Thermostable hydroxystyrylaza compounds | THE DOW CHEMICAL COMPANY (US) | 1986-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148777-A1 | Benzopyran compounds useful for treating inflammatory conditions | PTGES2, PTGER2, PTGS2 | ERN1 2661/4885IGF1R 2928/4885LMNA 3346/4885 |
| US-20100190783-A1 | TRIAZOLONE DERIVATIVES | H1-0, H1-10, H1-2 | ERN1 1354/4885IGF1R 476/4885LMNA 2146/4885 |
| US-20110112109-A1 | TRIAZOLONE DERIVATIVES | H1-10, H1-0, H1-2 | ERN1 1512/4885IGF1R 788/4885LMNA 1872/4885 |
| US-20100249165-A1 | PDZ DOMAIN MODULATORS | PDLIM5, PSD, PDCD6IP | ERN1 2349/4885IGF1R 3297/4885LMNA 4607/4885 |
| US-20050148627-A1 | Benzopyran compounds for use in the treatment and prevention of inflammation related conditions | PTGES2, PTGER2, PTGES | ERN1 3395/4885IGF1R 2344/4885LMNA 2102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.